Icon

TENORMIN (nda018240)- (25MG,50MG,100MG)

ATENOLOL TWI PHARMS
25MG,50MG,100MG
Yes No
Expired Expired
None None
None No
TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. TENORMIN is indicated for the long-term management of patients with angina pectoris due to Coronary Atherosclerosis. TENORMIN is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality.
9 0 8
Total Other Developers 4
Drugs with Suitability No
25MG ** ** - - 7
50MG ** ** - - 7
100MG ** ** - - 7
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******** *** ************ *** */*/* ***** ****** ********* *********** ***** ** **** *******, *****, ******* (**) *****, ****** ****** (***) ***
****** ***** ********** *** *** *********** ** ****** **, ****** ****, *** ****, ********* (***) ***
****** **** **** ***** ********** *.*.* *********** ********* ***/**, *******, *****, *** **, ***** ******** (***) ***
****** **** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ***** ****** *** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ***** ****** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ****** * * ********* *** *************** ******* *********** **** **. ***-***, *.*.*.* ********** ****, *******, ******, ***** (***) ***
****** ****** ****** ************** ************ (* ***. ** ** ********* & *************** ***) *********** **** **.*, ***** **, *.*.*.*. ********** ******, ******, *******, ******* ******, ***** (***) ***
****** ********* ****** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ***** ***** *************** ***. *********** **** ******* ***** ****, **********, **** ******** (**) *****, ****** ****** (***) ***
****** ***** ****** *** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.